USA flag logo/image

An Official Website of the United States Government

IGF::OT::IGF: FY13: Phenotypic Screening of Smoking Cessation Drugs, …

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
N43DA130037
Solicitation Year:
2013
Solicitation Topic Code:
NIDA
Solicitation Number:
Small Business Information
AFASCI, INC.
522 Second Avenue REDWOOD CITY, CA 94063-3848
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: IGF::OT::IGF: FY13: Phenotypic Screening of Smoking Cessation Drugs, N43DA-13-7
Agency: HHS
Contract: N43DA130037
Award Amount: $338,884.00
 

Abstract:

Under this Small Business Innovation Research (SBIR) Phase I project, Research Topic 149, the Contractor shall develop predictive in vivo screening systems for phenotypic drug discovery for smoking cessation. The Contractor shall accomplish this throughthe following objectives: Objective 1- Evaluate a battery of tests aimed at examining various components of nicotine addiction to be used for phenotypic drug discovery and development of smoking cessation medications. Objective 2- Phenotypically profilefour FDA approved smoking cessation drugs (varenicline, bupropion, clonidine and nortriptyline, each tested at three doses) and two controls (positive drug at an appropriate dose and negative with vehicle) using the behavioral tests/assays validated inObjective 1. PUBLIC HEALTH RELEVANCE

Principal Investigator:

Xinmin S. Xie
650-784-5658
SIMONXIE@AFASCI.COM

Business Contact:

Xinmin S. Xie
650-784-5658
SIMONXIE@AFASCI.COM
Small Business Information at Submission:

AFASCI, INC.
522 Second Avenue REDWOOD CITY, CA 94063-3848

EIN/Tax ID: 770605651
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No